Table S1.
Clinicopathological characteristics of the patients in this study
| Patient ID | Sex | Age, y | Grade | Ki-67, % | MGMT, % | LOH |
| GBM 1 | M | 66 | IV | 50 | 57 (M) | No |
| GBM 2 | F | 64 | IV | 30 | 54 (M) | 1p/19q |
| GBM 3 | F | 78 | IV | 35 | 62 (M) | No |
| GBM 4 | M | 64 | IV | 50 | 4 (UM) | No |
| GBM 5 | F | 63 | IV | 35 | 9 (UM) | 19q |
| GBM 6 | M | 53 | IV | 15 | 3 (UM) | No |
| GBM 7 | M | 36 | IV | 80 | 24 (M) | No |
The clinicopathological features of GBM patients used for organotypic glioma cultures (GBM 1 and 2) or neurosphere derivation (GBM 3–7) are indicated. F, female; M, male. Age (years) at diagnosis is indicated. Grade was estimated according to the fourth edition of the World Health Organization (WHO) classification of tumors of the central nervous system (48). The Ki-67 labeling index was considered in tumor hotspots as an indicator of glioma proliferation. The percentage of 06 methylguanine-DNA methyltransferase (MGMT) promoter methylation (by pyrosequencing analysis) and the resulting status (methylated if ≥20%, or unmethylated) is provided. M, methylated; UM, unmethylated. Loss of heterozygosity (LOH) at 1p/19q was analyzed.